实用医学杂志 ›› 2020, Vol. 36 ›› Issue (22): 3104-3109.doi: 10.3969/j.issn.1006⁃5725.2020.22.015

• 临床研究 • 上一篇    下一篇

基于倾向评分匹配的患者依从性对结直肠癌新辅助治疗疗效的影响

吕炘沂, 刘健博, 谢欣然, 龚佳祺, 汪晓东   

  1. 四川大学1华西临床医学院,2华西医院胃肠外科(成都610041)
  • 出版日期:2020-11-25 发布日期:2020-12-14
  • 通讯作者: 汪晓东E⁃mail:lockwan@qq.com

Effect of patient compliance based on propensity score matching on efficacy of neoadjuvant therapy for colorectal cancer

LÜ Xinyi,LIU Jianbo,XIE Xinran,GONG Jiaqi,WANG Xiaodong   

  1. West China School of Medicine,Sichuan University,Chengdu 610041,China
  • Online:2020-11-25 Published:2020-12-14
  • Contact: WANG Xiaodong E⁃mail:lockwan@qq.com

摘要:

目的 基于华西肠癌数据库(DACCA)探讨患者依从性是否会影响结直肠癌新辅助治疗疗效。方法 数据库版本为2019年11月14日,提取接受新辅助治疗的328例结直肠癌患者结构化资料,根据患者依从性程度分为完全依从组(n = 154)和部分依从组(n = 174)。依据患者基本资料、新辅助治疗情况、依从性等基线数据对病例进行1∶1的倾向评分匹配(PSM),每组成功匹配88例,对比分析两组新辅助治疗疗效。结果 倾向性匹配前,单因素分析显示两组结直肠癌患者依从性与BMI、体质、肿瘤部位、临床分期等因素无关(P > 0.05),而与患者年龄、性别及新辅助治疗周期相关(P < 0.05),且患者依从性程度与新辅助治疗周期呈正相关(rs = 0.366,P < 0.001),与患者年龄呈负相关(rs = -0.151,P = 0.006)。倾向性匹配后,两组临床缓解程度差异无统计学意义(P = 0.532),两组的病理退缩分级(TRG)差异无统计学意义(P = 0.612)。结论 对于接受新辅助治疗的结直肠癌患者而言,患者依从性尚不能作为一项预测或评估新辅助治疗疗效的有力指标。

关键词: 依从性, 结直肠癌, 新辅助治疗, 倾向评分匹配

Abstract:

Objective To investigate the effect of patient compliance on the efficacy of neoadjuvant therapyfor colorectal cancer based on the data from Database from Colorectal Cancer(DACCA). Method The version ofDACCA was updated on Nov.14th,2019. We extracted the structured data of 328 patients with colorectal cancerwho received neoadjuvant therapy,and patients were divided into complete compliance group(n = 154)and partialcompliance group(n = 174). A 1∶1 propensity score matching(PSM)was conducted according to basic data of thepatients,neoadjuvant therapy,patient compliance and other baseline data,and 88 cases were successfullymatched in each group. The efficacy of neoadjuvant therapy treatment was compared and analyzed between the twogroups. Results Before PSM,The compliance of the two groups of colorectal cancer patients was not associatedwith BMI,constitution,tumor location and clinical stage,(P > 0.05),but with age,gender and neoadjuvant therapytreatment cycle(P < 0.05). Additionally,the degree of compliance positively correlated with neoadjuvant therapytreatment cycle(rs = 0.366,P < 0.001),but negatively with age(rs = -0.151,P = 0.006). After PSM,there wasno statistically significant difference in clinical response degree between the two groups(P = 0.532),and in tumorregression grade(TRG)between the two groups(P = 0.612). Conclusions For patients with colorectal cancerreceiving neoadjuvant therapy,patient compliance cannot yet be used as a powerful indicator for predicting or eval⁃uating the efficacy of neoadjuvant therapy.

Key words: compliance, colorectal cancer, neoadjuvant therapy, propensity score matching